OPK - OPKO Health, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.23
-0.26 (-7.45%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.49
Open3.50
Bid0.00 x 800
Ask0.00 x 3000
Day's Range3.21 - 3.54
52 Week Range2.66 - 6.40
Volume5,527,478
Avg. Volume4,955,310
Market Cap1.808B
Beta (3Y Monthly)1.56
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Here Are Opko Health’s Major R&D Programs in 2018
    Market Realist15 hours ago

    Here Are Opko Health’s Major R&D Programs in 2018

    Opko Health (OPK) is focused on advancing multiple research and development (or R&D) programs including label expansion of Rayaldee and the development of novel therapies in 2018.

  • A Look at Opko Health’s Expense Projections for 2018
    Market Realist17 hours ago

    A Look at Opko Health’s Expense Projections for 2018

    Wall Street analysts expect Opko Health to report selling, general, and administrative (or SG&A) expenses of $365.60 million in fiscal 2018, which would be a YoY decline of 29.83%. The company is expected to witness SG&A expenses of $437.64 million in fiscal 2019, which would be a YoY rise of 19.70%. Wall Street analysts also expect Opko Health to report SG&A expenses of $491.90 million in fiscal 2020, which would be a YoY rise of 12.40%.

  • Rayaldee Is a Key Revenue Driver for Opko Health
    Market Realist18 hours ago

    Rayaldee Is a Key Revenue Driver for Opko Health

    In its third-quarter earnings conference call, Opko Health (OPK) forecasted its total product revenues to fall in the range of $28 million to $32 million in the fourth quarter. The company also reported Rayaldee sales of $5.8 million in the third quarter, which is a 21% rise on a sequential basis. Rayaldee witnessed a 222% YoY rise and an 18% sequential rise in prescription volumes in the third quarter.

  • Men’s Health Is a Key Focus Area for Opko Health
    Market Realist2 days ago

    Men’s Health Is a Key Focus Area for Opko Health

    Opko Health (OPK) is focused on advancing the penetration of its 4Kscore blood test. Opko Health has witnessed a 19% YoY rise in urologists performing 4Kscore blood tests in the 12 months ending September 2018. On May 18, Opko Health issued a press release announcing its plans to ensure Medicare coverage for the 4Kscore blood test despite the non-coverage policy proposed by Novitas Solutions.

  • What Opko Health Expects for Its Revenue in 2018
    Market Realist2 days ago

    What Opko Health Expects for Its Revenue in 2018

    In its third-quarter earnings conference call, Opko Health (OPK) forecasted that its revenues from services will fall in the range of $185 million to $205 million in the fourth quarter. Wall Street analysts expect Opko Health to report revenues of $1.04 billion in fiscal 2018, which would be a YoY decline of 2.59%. Wall Street analysts expect Opko Health to report revenues of $1.27 billion in fiscal 2020, which would be a YoY rise of 13.54%.

  • OPKO Health (OPK) Incurs Loss in Q3, Lags Revenue Estimates
    Zacks2 days ago

    OPKO Health (OPK) Incurs Loss in Q3, Lags Revenue Estimates

    OPKO Health (OPK) gains from robust demand for its flagship RAYALDEE in Q3; adjusted gross margin remains pressed.

  • What Analysts Recommend for Opko Health in November
    Market Realist2 days ago

    What Analysts Recommend for Opko Health in November

    On November 9, Opko Health (OPK) closed at $3.09, which was 11.46% lower than its previous closing price. The stock was trading 15.57% lower than its closing price of $3.66 on November 1. To know more about the major events that had a significant impact on Opko Health’s stock price, read Why Opko Health Rose 15% Yesterday.

  • Why Athenahealth, Apptio, and Opko Health Jumped Today
    Motley Fool2 days ago

    Why Athenahealth, Apptio, and Opko Health Jumped Today

    Find out how these stocks bucked the big downward move in the markets.

  • GuruFocus.com3 days ago

    World Stocks Red Monday

    OPKO Health advances on 3rd-quarter earnings and revenues

  • Why Opko Health Inc. Shares Soared Today
    Motley Fool3 days ago

    Why Opko Health Inc. Shares Soared Today

    Better-than-expected Q3 results give the beaten-down healthcare stock a spark.

  • Thomson Reuters StreetEvents5 days ago

    Edited Transcript of OPK earnings conference call or presentation 9-Nov-18 9:15pm GMT

    Q3 2018 OPKO Health Inc Earnings Call

  • OPKO Health (OPK) Reports Q3 Loss, Misses Revenue Estimates
    Zacks5 days ago

    OPKO Health (OPK) Reports Q3 Loss, Misses Revenue Estimates

    OPKO Health (OPK) delivered earnings and revenue surprises of 37.50% and -4.85%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press5 days ago

    OPKO Health: 3Q Earnings Snapshot

    The Miami-based company said it had a loss of 5 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of ...

  • Will OPKO Health (OPK) Report Negative Earnings Next Week? What You Should Know
    Zacks8 days ago

    Will OPKO Health (OPK) Report Negative Earnings Next Week? What You Should Know

    OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • 7 Biotech Stocks to Buy Now
    InvestorPlace2 months ago

    7 Biotech Stocks to Buy Now

    Now that the biotechnology sector is well on its way to bouncing back after bottoming in May 2018, investors may feel like they missed out. The fears that previously plagued biotech stocks are no longer as big a threat. The government is no longer putting companies hiking drug price in their cross-hairs, at least not for now. This favorable environment should help biotech firms carry out their plans for the rest of the year.

  • Why Opko Health Rose 15% Yesterday
    Market Realist2 months ago

    Why Opko Health Rose 15% Yesterday

    On September 7, the Securities and Exchange Commission (or SEC) announced that it would be filing charges against Opko Health’s (OPK) founder and CEO, Phillip Frost, and ten associated entities including Opko Health and Frost Gamma Investments Trust for indulging in fraudulent schemes to manipulate stock prices of certain companies. The agency claimed that a group of microcap fraudsters used classic pump-and-dump schemes and illegal promotional means to artificially inflate the stock prices of MabVax Therapeutics Holdings and BioZone Pharmaceuticals, which subsequently led to $27 million worth of illegal stock sales. Following these allegations, Opko Health stock fell 18.06% to $4.58 on September 7. Afterward, Nasdaq halted the trading of the stock and requested additional information from the company related to the SEC’s lawsuit.

  • Why Opko Health Rallied 15% Today
    Motley Fool2 months ago

    Why Opko Health Rallied 15% Today

    Investors are betting that a recent tumble will provide a good buy opportunity.

  • Billionaire health-care investor Phillip Frost charged by SEC with pump-and-dump schemes
    MarketWatch2 months ago

    Billionaire health-care investor Phillip Frost charged by SEC with pump-and-dump schemes

    Frost is a former chairman of Teva, and two of the companies involved in the alleges schemes were in the biopharmaceutical sector.

  • 3 Big Stock Charts for Monday: PG&E, Oracle and Weyerhaeuser
    InvestorPlace2 months ago

    3 Big Stock Charts for Monday: PG&E, Oracle and Weyerhaeuser

    It wasn’t a screaming bullish finish to the week, but it didn’t matter. The S&P 500’s 0.03% gain on Friday translated into a 1.1% advance for the five-day span. The close of 2,904.98 was the second-best close ever.

  • Why Westinghouse Air Brake Technologies, NiSource, and Opko Health Slumped Today
    Motley Fool2 months ago

    Why Westinghouse Air Brake Technologies, NiSource, and Opko Health Slumped Today

    Find out which of these stocks traded for the first time in a week.

  • Motley Fool2 months ago

    Why Opko Health, Inc. Shares Plunged Today

    Investors remained very worried about the SEC's allegations of fraud.

  • Are OPKO Health Inc (NASDAQ:OPK) Insiders Bullish About The Stock
    Simply Wall St.2 months ago

    Are OPKO Health Inc (NASDAQ:OPK) Insiders Bullish About The Stock

    OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. OPKO Health’s insiders have invested 444.52kRead More...

  • The SEC Takes Aim at Opko Health's Phillip Frost
    Motley Fool2 months ago

    The SEC Takes Aim at Opko Health's Phillip Frost

    Phillip Frost and Opko Health have been charged with allegedly manipulating stock prices.

  • Benzinga2 months ago

    Opko Health Under Fire From The SEC; Mark Cuban Confirms He's Short The Stock

    Financier Barry Honig,  Opko Health Inc. (NASDAQ: OPK ) and  Riot Blockchain, Inc. (NASDAQ: RIOT ) CEO John O'Rourke were among those named as defendants in a securities fraud lawsuit filed Friday by the ...